Gadolinium-based contrast agents (GBCAs) used for MRI are known to cause gadolinium depositions in the brain. In this study we show that the using quantitative MRI we can detect gadolinium depositions after fewer doses of GBCAs than generally seen on conventional MRI. We included 43 patients that were earlier enrolled in a prospective longitudinal cohort study of early Multiple Sclerosis. All patients had received the linear GBCA Magnevist. Measurements of the longitudinal relaxation rate R1 showed a significant increase in dentate nuclei, globi pallidi and frontal grey matter.